Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 25 Advanced Breast Cancer 2 Sarcoma, Endometrial Stromal 1 Recurrence 1 Perivascular Epithelioid Cell Neoplasms 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Endometrial Neoplasms 1 ESR1 Gene Mutation 1 ER+ Breast Cancer 1 Central Nervous System Neoplasms 1 Central Nervous System Diseases 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Neoplasms, Male 1 Breast Diseases 1 Breast Cancer Patients 1 Brain Neoplasms 1 Brain Diseases 1 Advanced ER+, HER2-Negative Breast Cancer 1 Adenosarcoma of the uterus 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

ESR1 Gene Mutation × elacestrant × Clear all

NCT06544577 2024-08-09

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

SciClone Pharmaceuticals

ESR1 Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon ⚡